Advancing EXL01 Through Clinical Trials & Mechanistic Discovery to Enable Immune Modulation Across Diseases
- Sharing updates from EXL01’s active Phase II trials in gastric cancer, NSCLC, hepatocellular carcinoma, Crohn’s disease, and C. difficile infection
- Present early clinical signals from investigator-led studies, including preliminary data in infection and IBD
- Highlight EXL01’s NOD2-targeted mechanism enabling immune modulation without gut colonisation